Skip to content

Madrigal Pharmaceuticals

US · MDGL #1355 by market cap Listed 2016
379.10 -17.64 -4.45%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 15.84 In line with history 53rd percentile
5-year average 43.73 · #479 of 514 in Biotechnology
P/E ratio -53.09 Cheap vs history 0th percentile
5-year average -17.49 · forward 49.42
P/S ratio 6.95 In line with history 55th percentile
5-year average 28.07 · forward 4.87 · #149 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Madrigal Pharmaceuticals (MDGL) 8.81B -47.09 14.05 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value378.94 Economic moatNone UncertaintyHigh

Trading 0.0% above Morningstar's fair value estimate.

Fair value

Madrigal Pharmaceuticals Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 13% premium over our quantitative fair value estimate of $378.94 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's lack of profitability weakens our fair value estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its enterprise value to free cash flow ratio, which lies in the top 1% compared with global peers. This suggests limited cash flow is available for reinvestment or return to shareholders, which contributes to our view that shares are expensive.

The firm's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 6.8%, a core component of valuation, sits in the bottom 10% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Madrigal Pharmaceuticals discussion 0 comments

Add a comment